Leading Manufacturing Companies -Biocon Limited

Today, Biocon has its mark made far beyond traditional businesses, having become the first company in the world to have a biosimilar monoclonal antibody approved in the United States of America. The approval for Trastuzumab in late 2017 represents a culmination of the efforts of the better part of the previous decade.
“As for supply chain, adapting each of its functions, making them further capable of enabling the company’s biologics dream, has been the focal point of the company’s evolutionary changes,” states Deshpande.
Sourcing for biologics has been markedly different from traditional procurement: the focus being more on supply assurance and risk mitigation than on cost. Capabilities in controlled shipments have improved remarkably with Biocon, today, being capable of delivering a wide range of temperature-controlled shipments across the globe. Overcoming geo-political equations has been a challenge and expertise in shipping to countries where cold-chain infrastructure is, at best, modest has been at the forefront of the company’s promise of delivering affordable innovation in the remotest of regions.
Deshpande feels that GST is expected to reduce complexity, save time, cost and efforts of all links of supply chain. “The transition to the new regime has been reasonably smooth, and it has since opened up new functional areas in compliance and value creation. There is consensus that pharmaceutical companies would enjoy improved operational efficiency, reduced manufacturing & transaction costs, resulting in more affordable drugs,” he proclaims.